• Title/Summary/Keyword: Pleural metastasis

Search Result 60, Processing Time 0.03 seconds

A Case of a Huge Mass Due to Pleural Metastasis and Management of Dyspnea in a Patient with Terminal Breast Cancer (말기 유방암 환자에서 발생한 흉막 전이에 의한 거대 종양 1예와 호흡곤란의 치료)

  • Lee, Na Ri
    • Journal of Hospice and Palliative Care
    • /
    • v.17 no.2
    • /
    • pp.85-89
    • /
    • 2014
  • Pleural metastasis from breast cancer is a common manifestation. While pleural effusion is the most frequent finding, it is relatively rare for pleural nodularity and plaque that do not accompany pleural effusion. We report a patient with a rapidly growing huge pleural mass without pleural effusion caused by breast cancer. The patient was treated for severe dyspnea caused by the pleural mass. Along with the case report, we performed a systematic review of management of dyspnea in terminal cancer patients.

The Role of Primary Tumor Resection in Patients with Pleural Metastasis Encountered at the Time of Surgery

  • Park, Samina;Chung, Yongwoo;Lee, Hyun Joo;Park, In Kyu;Kang, Chang Hyun;Kim, Young Tae
    • Journal of Chest Surgery
    • /
    • v.53 no.3
    • /
    • pp.114-120
    • /
    • 2020
  • Background: Evidence is lacking on whether the resection of lung parenchymal cancer improves the survival of patients with unexpected pleural metastasis encountered during surgery. We conducted a single-center retrospective study to determine the role of lung resection in the long-term survival of these patients. Methods: Among 4683 patients who underwent lung surgery between 1995 and 2014, 132 (2.8%) had pleural metastasis. After excluding 2 patients who had incomplete medical records, 130 patients' data were collected. Only a diagnostic pleural and/or lung biopsy was performed in 90 patients, while the lung parenchymal mass was resected in 40 patients. Results: The mean follow-up duration was 29.8 months. The 5-year survival rate of the resection group (34.7%±9.4%) was superior to that of the biopsy group (15.9%±4.3%, p=0.016). Multivariate Cox regression analysis demonstrated that primary tumor resection (p=0.041), systemic treatment (p<0.001), lower clinical N stage (p=0.018), and adenocarcinoma histology (p=0.009) were significant predictors of a favorable outcome. Interestingly, primary tumor resection only played a significant prognostic role in patients who received systemic treatment. Conclusion: When pleural metastasis is unexpectedly encountered during surgical exploration, resection in conjunction with systemic treatment may improve long-term survival, especially in adenocarcinoma patients without lymph node metastasis.

Pleural Metastasis of Lung Cancer Combined with Pleuroparenchymal Fibroelastosis: A Case Report (흉막폐실질 탄력섬유증과 동반된 폐암의 흉막 전이: 증례 보고)

  • Sung Cheol Hong;Lucia Kim;Min Kyung Lee;Hong Lyeol Lee;Kyung Hee Lee
    • Journal of the Korean Society of Radiology
    • /
    • v.85 no.3
    • /
    • pp.631-636
    • /
    • 2024
  • Pleural metastasis is the most common cause of malignant diseases involving the pleura, and characterized by pleural effusion, nodules, and thickening. Pleuroparenchymal fibroelastosis (PPFE) is a disease characterized by apical pleural thickening and subjacent parenchymal fibrosis. We report a case of a 60-year-old male with lung cancer in the left lower lobe and underlying PPFE combined with left apical pleural metastasis. Initially, asymmetric left apical pleural thickening due to pleural metastasis was mistaken for PPFE. Additionally, we describe the imaging and histopathological findings of PPFE, including MRI findings.

A Case Report of Korean Medicine Treatment for Pleural Effusion due to Metastasis of Breast Cancer (유방암의 폐전이로 인한 흉막 삼출의 한의치료에 대한 증례보고)

  • Moon, Jiseong;Kim, Hakkyeom;Kim, Yeseul;Min, Seonwoo;Park, Jiyoon;Ahn, Lib
    • The Journal of Internal Korean Medicine
    • /
    • v.42 no.3
    • /
    • pp.420-430
    • /
    • 2021
  • The survival time of breast cancer patients with lung metastasis has been prolonged as treatment methods have improved. However, there is yet no definitive therapy for the additional symptoms of lung metastasis to improve the quality of life of these patients. We report a patient who was suffering from pleural effusion due to metastasized breast cancer. She was treated with Korean medicine, including herbal medicine (Bojungikgi-tang-gami), combined with hormone therapy, for two months. We assessed her other symptoms, such as shortness of breath, generalized weakness, and lower extremity swelling, using a numeric rating scale (NRS). We also evaluated pleural effusion with chest X-rays. Shortness of breath was maintained at NRS 5, generalized weakness was slightly improved from NRS 6~7 to NRS 7~8 (10=healthy condition), and lower extremity edema was improved from NRS 3 to NRS 2 (10=highest score of discomfort). Malignant pleural effusion was maintained during the admission period. This report suggests that Korean medicine can help to maintain malignant pleural effusion and improve additional symptoms of lung metastasis.

A Case of Pleural Metastasis 6 Years after Complete Surgical Resection of Invasive Thymoma

  • Woo, Kwang-Jin;Kim, Yang-Ki;Kim, Ki-Up;Uh, Soo-Taek;Kim, Dong-Won;Hwang, Jung-Hwa;Kim, Yong-Hoon;Park, Choon-Sik
    • Tuberculosis and Respiratory Diseases
    • /
    • v.70 no.1
    • /
    • pp.74-78
    • /
    • 2011
  • Herein, we report a case of recurrent pleural metastasis after complete resection of invasive thymoma that was successfully treated with surgical resection. Thymoma and thymic carcinoma are uncommon neoplasms derived from the epithelial cells of the thymus. Approximately 30% to 50% of thymomas are asymptomatic at the time of diagnosis. However, these cancers may present with constitutional or local pressure symptoms and sometimes with paraneoplastic syndromes, especially myasthenia gravis. Surgical resection is the mainstay of thymoma treatment and has been shown to remarkably improve long-term survival. Despite complete resection, local recurrences are frequent, and surgery is the cornerstone of therapy even in cases of recurrent thymoma. We experienced a 67-year-old male patient with pleural metastasis that developed 6 years after complete surgical resection of invasive thymoma. The pleural mass was excised by video-assisted thoracoscopic surgery. Histopathological examination revealed an invasive World Health Organization (WHO) type B2 thymoma.

Massive Pleural Effusion as the First Manifestation of Malignant Melanoma Metastasis (흉수로 발현한 전이성 악성 흑색종 1예)

  • Kim, Hee Gu;Ryu, Jeong Seon;Kwak, Seung Min;Lee, Hong Lyeol;Kim, Lucia;Cho, Jae Hwa
    • Tuberculosis and Respiratory Diseases
    • /
    • v.57 no.3
    • /
    • pp.289-291
    • /
    • 2004
  • Malignant melanoma develops from melanocytes and frequently metastases to other organs. Common metastatic sites are other skin, lymph nodes, lung, liver, brain and bone in decreasing order of frequency. Malignant pleural effusion is less frequent manifestation of thoracic metastasis. We experienced a 57-year-old man with pleural effusion who received radical resection with local flap on left foot due to acral lentiginous melanoma 3 years ago. He had progressive chest pain and left massive pleural effusion. The pleural cytology and biopsy showed malignant melanoma. After closed thoracostomy and talc pleurodesis, he refused further immunotherapy and chemotherapy and discharged.

Occult Papillary Thyroid Carcinoma Presenting as a Metastatic Pleural Effusion (전이성 흉수로 발현된 잠재성 유두상 갑상선암)

  • Lee, Kye-Young;Myong, Na-Hye;Kim, Keun-Yeol
    • Tuberculosis and Respiratory Diseases
    • /
    • v.42 no.4
    • /
    • pp.594-599
    • /
    • 1995
  • Although papillary carcinoma of the thyroid generally follows an indolent course characterized by slow growth and the absence of distant metastases, several available reports suggest that metastasis to bone and/or lung parenchyma may occur infrequently. But pleural metastases are known to be very rare, so there have been only two case reports about the pleural metastases of papillary thyroid carcinoma in the literatures. Even the case of occult papillary thyroid carcinoma presenting as a metastatic pleural effusion has been never been reported. Recently we experienced a case with the chief complaint of dyspnea due to massive pleural effusion, the cytologic examination of which revealed the papillary carcinoma with psamomma bodies. The examination of the thyroid revealed no definite primary tumor. The total thyroidectomy was done with the plan of post-operative radioactive iodine treatment and the pathologic result confirmed the occult papillary microcarcinoma as expected. With the present case report, the extension of the clinical spectrum. of metastatic papillary carcinoma of the thyroid is expected.

  • PDF

Pleural Metastasis of Atypical Bronchial Carcinoid

  • Zinchenko, Eugeniy Igorevich;Maslak, Olga Sergeevna;Pischik, Vadim Grigorievich;Obornev, Aleksandr Dmitrievich;Kovalenko, Aleksandr Igorevich
    • Journal of Chest Surgery
    • /
    • v.53 no.5
    • /
    • pp.317-320
    • /
    • 2020
  • Pulmonary carcinoids are relatively rare tumors with low metastatic potential. Pleural carcinomatosis of a bronchial carcinoid has only been reported in 4 cases. Due to the rarity of this condition, there are no guidelines for its treatment or management. We report a case of atypical carcinoid with local recurrence and pleural metastases treated by video-assisted thoracoscopic surgery lobectomy and total pleurectomy with photodynamic therapy after non-radical wedge resection.

Empyema and Pericarditis by Salmonella Group D Complicating Malignant Thymoma with Pleural Metastasis (흉선종의 흉막전이에 동반된 Group D Salmonella 농흉 및 심낭염 -1예 보고-)

  • 조덕곤;조민섭;송소향;김치홍;이선희;조규도
    • Journal of Chest Surgery
    • /
    • v.37 no.4
    • /
    • pp.382-385
    • /
    • 2004
  • Non-typhoid salmonella infection frequently associated with bacteremia rarely been reported in immunocom-promized patients with malignant neoplasms, diabetes or extended use of corticosteroids. Especially, concomitant pleural empyema and pericarditis due to non-typhoid salmonella. infection is extremely rare. Here, we report a case of concomitant empyema and pericarditis in malignant thymoma with pleural. metastasis complicated by salmonella group D infection with brief review of literature.

A Case of Lung Cancer: Postop Minimal Residual Disease at Pleura (폐암 수술 후 흉막 내 미세잔류병변 판정사례)

  • Jang, JoungSoon
    • Korean journal of aerospace and environmental medicine
    • /
    • v.31 no.2
    • /
    • pp.57-59
    • /
    • 2021
  • For nonsmall cell lung cancer (NSCLC), surgery is indicated only for stage 3 as a curative measure. Even so, there is a high risk of recurrence following stage 3 lung cancer surgery, a third (33.9%) of patients experienced a cancer recurrence mostly within 2 years after surgery. The median survival time for all stages reaches only 21.9 months. For people undergoing surgery for stage 3A NSCLC, a pre-operative course of (neoadjuvant chemotherapy) can improve survival times, by improving the resectability and lowering the risk of recurrence. Pleural metastases are frequently associated with tumors of the lung and breast. Chest radiographs and computed tomography scans of pleural metastases can present as an effusion or smooth or nodular pleural thickening. In the absence of irregular or nodular pleural thickening, it is difficult to distinguish a benign from a malignant pleural effusion. To treat lung cancer, tyrosine kinase inhibitors (TKIs) recently have been used to cope with genetic mutations, apart from cytotoxic anticancer drugs. Compared to cytotoxic drugs, they are effective, have fewer side effects, and are easy to administer. Airman must have no cancer disease to apply for Class-I medical certification. Specifically, if previously operated on cancer, the cancer should not remain in the body at present, and the disease free state should persist at least one year after all kinds of anti-cancer treatments including adjuvant chemotherapy are completed. Here, this case deals with a 41-year-old pilot who has ATP license who had stage 3A NSCLC. The pilot underwent curative lung cancer surgery (lobectomy) a year ago and showed suspicious pleural metastasis at the time of his application for certification and was still using an unauthorized TKI agent alectinib (Alecensa; Roche, Basel, Switzerland).